Aurenar, a medical technology company based in St. Louis, has secured $5.7 million in an oversubscribed seed financing round to advance its V-Link neuromodulation platform for intensive care patients, according to reports from HLTH.com and Trend Hunter. The funding aims to support final device engineering, verification and validation testing, and preparations for FDA pivotal trials.
Financing Details and Investors
As reported by HLTH.com, the seed financing round was jointly led by Solas BioVentures and the Go Red for Women Venture Fund, an initiative of American Heart Association Ventures. Additional capital came from BJC Health and Kaleida Capital. The $5.7 million injection will finance the next development milestones for the St. Louis-based medical technology firm as it moves toward clinical regulatory submissions.
How the V-Link Platform Works
The V-Link system is a non-invasive transauricular vagus nerve stimulation (taVNS) device designed to reduce life-threatening inflammatory responses in intensive care patients. The platform uses a wireless, single-use ear-worn device to deliver targeted electrical stimulation to the auricular branch of the vagus nerve. By activating the body’s cholinergic anti-inflammatory pathway without surgical implantation, the technology integrates into existing neuro-intensive care workflows while avoiding the complexities of traditional implantable neuromodulation devices, as reported by HLTH.com.
Clinical Research at Washington University
Clinical research conducted at Washington University in St. Louis demonstrated positive outcomes for the technology. Studies led by Dr. Eric Leuthardt and Dr. Anna Huguenard revealed that moderate-to-severe cerebral vasospasm was cut by over 40% through the application of transauricular vagus nerve stimulation. Furthermore, data cited by HLTH.com indicated that the system lowered critical pro-inflammatory cytokines—specifically TNF-alpha and IL-6—within cerebrospinal fluid and blood plasma, enhanced functional recovery, and helped lower 30-day modifiable hospitalization costs by 20%.
Clinical Objectives in Critical Care
Dr. Eric Leuthardt, founder and CEO of Aurenar, noted the broader challenges of critical care environments. “In the intensive care unit, it’s not just the diagnosis that brings you in, it’s all of the things that happen afterwards that define a patient’s outcome,” Leuthardt stated, according to HLTH.com. With the new financial backing, the company intends to complete its verification and validation testing to bring the bioelectric therapeutic approach closer to clinical deployment in critical care settings.
Worth a look